Journal Watch · Clinical Pharmacology & Therapeutics · 2026

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT<sub>3</sub> Receptor Antagonists: 2026 Update.

We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT<sub>3</sub> receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).

Moore C, Bourque MS, Halman A et al.Clinical Pharmacology & Therapeutics3 min readPharma relevance 60/100

DOI: 10.1002/cpt.70291PMID: 41979467Study type: research study

TL;DR

We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT<sub>3</sub> receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).

Key findings

  • We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT<sub>3</sub> receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).

What they did

CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables.

Full abstract (original)

Background: 5-hydroxytryptamine type 3 (5-HT<sub>3</sub>) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. Most of the 5-HT<sub>3</sub> receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies.

What they did: CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables.

Results & conclusions: We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT<sub>3</sub> receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).

Abstract © the authors / Clinical Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/cpt.70291 · PubMed 41979467.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Clinical Pharmacology & Therapeutics study find?

We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT<sub>3</sub> receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).

What type of study is this?

It is a research study, published in Clinical Pharmacology & Therapeutics in 2026. CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/cpt.70291. PubMed ID: 41979467. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Moore C, Bourque MS, Halman A et al.. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT&lt;sub&gt;3&lt;/sub&gt; Receptor Antagonists: 2026 Update.. Clinical Pharmacology & Therapeutics (2026). DOI: 10.1002/cpt.70291.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-c-t70291/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides